On Jan 26, Pfizer and Astellas Pharma announced that the European Medicines Agency (EMA) has accepted to review a Type II variation application for the combined use of PADCEV® and KEYTRUDA®.

Hydrochlorothiazide, a small molecule drug, targets the NCC co-transporter as an inhibitor, exhibiting an assortment of therapeutic effects.

KEYTRUDA® (Pembrolizumab) Enhances Disease-Free Survival (DFS) as Adjuvant in High-Risk Urothelial Carcinoma Post-Surgery.

Tizanidine Hydrochloride, a minuscule molecule drug, is a potent agonist that targets the ADRA2 receptor with high specificity.

Dupixent® has been granted FDA approval as the exclusive therapy indicated for pediatric patients over the age of 1 diagnosed with eosinophilic esophagitis (EoE).

Bupropion Hydrochloride is a tiny molecule drug that targets multiple functions, including dopamine transporter (DAT), adrenergic receptor, and CYP2D6.

Orion Presents New Insights from Phase II CYPIDES Trial on ODM-208 at 2024 ASCO Symposium.

Phentermine, a small molecular compound, targets the TAAR1 receptor as an agonist and serves as an appetite suppressant for obesity management.

Lorazepam, a minute molecular compound, acts as an agonist that targets the GABAA receptor.

Cetirizine Hydrochloride, a minuscule molecule with a multifaceted pharmacological profile, operates as a potent and selective H1 receptor antagonist.

Claritin (loratadine) is an oral, second-generation antihistamine used for treating allergies like hay fever and hives.

WELLBUTRIN® (bupropion hydrochloride) is an aminoketone antidepressant indicated for the treatment of major depressive disorder (MDD).